Managing clinical conditions: Fuch’s dystrophy

Article

Paul Karpecki, OD, FAAO, and Jill Autry, OD, RPh, shared Fuch's dystrophy management pearls with attendees at the American Optometric Association’s Optometry’s Meeting.

 

Philadelphia-Paul Karpecki, OD, FAAO, and Jill Autry, OD, RPh, shared clinical management pearls with attendees at the American Optometric Association’s Optometry’s Meeting.

In the past three years, more ODs bought specular microscopes than ophthalmologists, says Dr. Karpecki. Some 78 percent of ODs have pachymeters in the office as well. These instruments allow ODs to help manage certain clinical conditions.

Consider these four clinical stages of Fuch’s dystrophy before referring a patient with this condition.

• Guttata

• Stroma edema with decreased vision, worse in the morning

• Epithelium edema, including pain with ruptured bullae and further decrease in vision

• Corneal scarring

"If the epithelium can't pump, that's when we have problems," says Dr. Autry.

Says Dr. Karpecki: It’s time to start educating the patient about future surgical options, such as transplant, with these clinical signs:

• Morning blur that lasts a significant amount of time, such as >30 minutes

• Pachymeters over 600 µm in a patient who previously had normal (~550 µm) corneal thickness

• Specular microscopy signs

• First cataract surgery resulted in endothelial decompensation

Treatment for Fuch’s dystrophy includes:

• Observation

• Muro 128 5% solution/ung; a generic is available at half the price of brand; order online for better pricing

• FreshKote

110 mm Hg oncotic pressure pull

More comfortable daytime drop

• Lowering IOP may reduce stromal and epithelial edema

• Avoid carbonic anhyrase inhibor (CAI) medications because will further impede pumping action

• Bandage contact lens pm

Dr. Autry suggested trying a brand name medication if the results are acceptable. “If you're not hitting what you expect with a generic medication, try something else,” she says. “The eye is so good at keeping things off of it, even a small change in pH could make a difference.”

An attendee asked Drs. Autry and Karpecki if a scleral lens would be a good option for Fuch’s patient. Good question, says Dr. Karpecki. “Some people believe the one contraindication to a scleral is a compromised cornea. With newer lenses, it may not be the case. It's still a debatable question.”ODT

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.